Breast Cancer

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar safety profile that requires multidisciplinary collaboration to optimally treat.

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable to prior reports of each individual agent.

According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer, enhancing patient outcomes and safety.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Although the ORR was similar among patients treated with sacituzumab govitecan vs chemotherapy for TNBC, the DOR was higher with sacituzumab govitecan.

Gedatolisib enhanced PFS in advanced breast cancer, showcasing significant benefits when combined with fulvestrant and palbociclib.

T-DXd followed by THP is more effective and less toxic than dose-dense doxorubicin and cyclophosphamide then THP in this breast cancer population.